Akero Therapeutics

Our CSO, Timothy rolph, has co-authored a new article in the Journal of Hepatology , highlighting the impact of FGF21 on a novel signaling pathway implicated in MASH. The original research by Liu, Wei, Jiang and colleagues reveals how FGF21 inhibits mTORC1, a key regulator of metabolism, to help clear liver fat by stimulating autophagy, a vital cellular clean-up process. FGF21 is also known to enhance insulin sensitivity which would be expected to inhibit autophagy. The novel signaling pathway described by Liu et al could explain the conundrum of how FGF21 is simultaneously able to increase autophagy and insulin sensitivity. Our investigational therapy, efruxifermin (EFX), and other FGF21 analogs have shown clinically significant reductions in liver fat and resolution of steatohepatitis. The work described in this editorial expands our understanding of FGF21's direct actions on hepatocytes, offers valuable insights into the therapeutic mechanisms of these emerging MASH treatments, and paves the way for further investigation into these pathways. Learn more: https://lnkd.in/gEpnHYuP #MASH #FGF21 #Hepatology #EFX #DrugDevelopment

We recently wrapped up meetings with clinical trial investigators in Chile and Argentina, and it was an honor to connect with those working with patients every day. These meetings are more than site visits—they represent our commitment to expanding clinical trial access for metabolic diseases like MASH and MASLD across the globe, especially in regions like Latin America where communities are disproportionately impacted by liver diseases such as MASH. Thank you to our clinical investigators and teams in Latin America for their warm hospitality and continued commitment to advancing science that makes a difference. Hospital Clínico Universidad de Chile - CeCim - Centro de Estudios Clínicos e Investigaciones Médicas - Clínica Universidad de los Andes - Estudios Clínicos CICUC - Fundación Sanatorio Güemes - Gedyt S. A. – CINME - Buenos Aires Macula - DIM Centros de Salud - Hospital Italiano de Buenos Aires - Hospital provincial del Centenario - Valsanza #ClinicalTrials #MASH #MASLD

Our CEO, Andrew Cheng, sat down with Roderick Wong from RTW Investments, LP to talk about our MASH program, the science behind it, and the persistence it took to get here. From early challenges to breakthrough moments, this episode covers the journey that brought us to where we are today.

This Global Fatty Liver Day, we’re joining the global movement to #ActNowScreenToday. Up to 20% of people with fatty liver disease are considered lean (≤24.9 BMI), meaning you don’t need to be overweight (≥25.0 BMI) to be at risk. Metabolic diseases such as MASLD and MASH can often go undetected, that’s why early screening is the first step to prevention or intervention.   Check out www.fattyliverday.org by the Global Liver Institute to learn more about fatty liver disease and how early screening can make all the difference.   #FattyLiverDay #FattyLiverDisease #MASH

Did you know men are more likely to develop MASLD and MASH earlier in life than women? These silent, progressive liver diseases are linked to metabolic dysfunction and often go undetected until advanced stages. This #MensHealthWeek, we’re calling for more awareness and urging men everywhere to stay up to date with their regular checkups. A simple conversation with your doctor could change everything. #MASH #MASLD #MensHealth

Join us tomorrow at the Jefferies Global Healthcare Conference in New York, NY! Can’t make it in person? Tune in to our live corporate presentation tomorrow, June 4th at 8:45 AM ET. Learn more: https://lnkd.in/eccaf8ER

Today Akero reported Q1 2025 financial results and provided business updates. Read more at: https://lnkd.in/e48rukEk

#EASL25 is well under way! We’re glad to be in attendance presenting new analyses from our Phase 2b HARMONY study. Don’t miss our oral presentation today at 10:30 CET and stop by our poster anytime between 8:30-16:00 CET to learn more. Read more: https://lnkd.in/eXF6dd5z

Today, Akero announced the publication of results from the Phase 2b SYMMETRY study in the @New England Journal of Medicine. Results support the potential benefit of #EFX to elicit fibrosis improvement in patients with compensated cirrhosis (F4 fibrosis) due to MASH. Learn more: https://lnkd.in/ezEYUFbC

Goedendag from the Netherlands! Today at #EASL25 we shared results from the Phase 2b SYMMETRY study demonstrating the potential of efruxifermin (EFX) to improve fibrosis in compensated cirrhosis (F4) caused by #MASH. Read more: https://lnkd.in/eDzj_tcV